AST 915

Drug Profile

AST 915

Alternative Names: AST-914; AST-914 metabolite; AST-915

Latest Information Update: 25 Apr 2014

Price : $50

At a glance

  • Originator Ariston Pharmaceuticals
  • Developer TG Therapeutics Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Essential tremor

Most Recent Events

  • 07 Mar 2014 Discontinued - Phase-I/II for Essential tremor in USA (PO)
  • 26 Apr 2012 Clinical development is ongoing in USA
  • 03 Feb 2011 Manhattan Pharmaceuticals plans to advance AST 915 into phase II development for Essential Tremor in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top